Skip to content
Pharma Observatory a Scientist.com platform

Condition (MeSH)

Neoplasms, Connective and Soft Tissue

ClinicalTrials.gov lists 3,782 trials for Neoplasms, Connective and Soft Tissue or a narrower condition beneath it. National Cancer Institute (NCI) has the most among industry and government lead sponsors, with 242.

MeSH D018204 Neoplasms Neoplasm C04
Email me this page as a PDF

Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Phase 1 Phase 1 657 Phase 1/2 Phase 1/2 300 Phase 2 Phase 2 1,063 Phase 2/3 Phase 2/3 37 Phase 3 Phase 3 275 Phase 4 Phase 4 97 Not applicable Not applicable 590 Observational Observational 726 Phase 1 Phase 1 657 Phase 1/2 Phase 1/2 300 Phase 2 Phase 2 1,063 Phase 2/3 Phase 2/3 37 Phase 3 Phase 3 275 Phase 4 Phase 4 97 Not applicable Not applicable 590 Observational Observational 726

Trials per phase (log scale)

2 more sections with rows

15 of the 3,782 trials are tagged with Neoplasms, Connective and Soft Tissue itself; the rest are tagged with a narrower condition beneath it.

Get the Neoplasms, Connective and Soft Tissue report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

When did Neoplasms, Connective and Soft Tissue trials start? (37)

Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year. 13 trials are registered to start in 2027 or later, and not listed here.

Trials over time, by phase

  • Phase 1
  • Phase 1/2
  • Phase 2
  • Phase 2/3
  • Phase 3
  • Phase 4
  • Not applicable
  • Observational
  • Other (Unknown)

Top of scale: 211

1990: 3 trials (Observational 1, Not applicable 1, Phase 2 1) 1991: 3 trials (Phase 2 2, Phase 1 1) 1992: 6 trials (Observational 3, Phase 3 2, Phase 2 1) 1993: 6 trials (Observational 2, Phase 3 2, Phase 2 2) 1994: 5 trials (Phase 3 2, Phase 2 2, Phase 1 1) 1995: 10 trials (Observational 3, Phase 3 3, Phase 2 2, Phase 1 2) 1996: 20 trials (Observational 2, Phase 3 4, Phase 2 10, Phase 1 4) 1997: 31 trials (Observational 4, Not applicable 1, Phase 3 3, Phase 2 13, Phase 1/2 2, Phase 1 8) 1998: 35 trials (Observational 9, Not applicable 1, Phase 3 3, Phase 2 13, Phase 1/2 1, Phase 1 8) 1999: 31 trials (Observational 4, Phase 3 1, Phase 2 18, Phase 1/2 3, Phase 1 5) 2000: 51 trials (Observational 11, Not applicable 1, Phase 3 2, Phase 2 20, Phase 1/2 5, Phase 1 12) 2001: 53 trials (Observational 6, Not applicable 5, Phase 3 4, Phase 2 18, Phase 1/2 6, Phase 1 14) 2002: 42 trials (Observational 9, Phase 3 7, Phase 2 21, Phase 1/2 2, Phase 1 3) 2003: 57 trials (Observational 3, Not applicable 4, Phase 4 2, Phase 3 10, Phase 2 29, Phase 1/2 2, Phase 1 7) 2004: 73 trials (Observational 8, Not applicable 8, Phase 4 2, Phase 3 7, Phase 2 26, Phase 1/2 5, Phase 1 17) 2005: 87 trials (Observational 17, Not applicable 7, Phase 4 1, Phase 3 4, Phase 2 37, Phase 1/2 4, Phase 1 17) 2006: 83 trials (Observational 11, Not applicable 11, Phase 4 2, Phase 3 9, Phase 2/3 2, Phase 2 30, Phase 1/2 4, Phase 1 14) 2007: 98 trials (Other 1, Observational 15, Not applicable 7, Phase 4 2, Phase 3 10, Phase 2/3 2, Phase 2 35, Phase 1/2 6, Phase 1 20) 2008: 110 trials (Observational 21, Not applicable 9, Phase 4 7, Phase 3 14, Phase 2/3 3, Phase 2 41, Phase 1/2 6, Phase 1 9) 2009: 94 trials (Observational 16, Not applicable 11, Phase 4 2, Phase 3 14, Phase 2 31, Phase 1/2 6, Phase 1 14) 2010: 130 trials (Observational 27, Not applicable 14, Phase 4 6, Phase 3 13, Phase 2/3 3, Phase 2 40, Phase 1/2 8, Phase 1 19) 2011: 131 trials (Observational 23, Not applicable 22, Phase 4 4, Phase 3 12, Phase 2/3 3, Phase 2 38, Phase 1/2 6, Phase 1 23) 2012: 123 trials (Observational 19, Not applicable 24, Phase 4 3, Phase 3 11, Phase 2/3 2, Phase 2 36, Phase 1/2 5, Phase 1 23) 2013: 98 trials (Observational 17, Not applicable 21, Phase 4 4, Phase 3 5, Phase 2 24, Phase 1/2 9, Phase 1 18) 2014: 139 trials (Observational 30, Not applicable 22, Phase 4 6, Phase 3 7, Phase 2/3 2, Phase 2 37, Phase 1/2 13, Phase 1 22) 2015: 149 trials (Observational 28, Not applicable 25, Phase 4 7, Phase 3 7, Phase 2/3 2, Phase 2 41, Phase 1/2 13, Phase 1 26) 2016: 155 trials (Observational 33, Not applicable 30, Phase 4 5, Phase 3 9, Phase 2/3 3, Phase 2 28, Phase 1/2 13, Phase 1 34) 2017: 169 trials (Observational 29, Not applicable 23, Phase 4 7, Phase 3 17, Phase 2/3 2, Phase 2 50, Phase 1/2 19, Phase 1 22) 2018: 179 trials (Observational 32, Not applicable 33, Phase 4 4, Phase 3 16, Phase 2/3 1, Phase 2 45, Phase 1/2 21, Phase 1 27) 2019: 179 trials (Observational 38, Not applicable 32, Phase 4 6, Phase 3 8, Phase 2 49, Phase 1/2 15, Phase 1 31) 2020: 193 trials (Observational 33, Not applicable 41, Phase 4 6, Phase 3 8, Phase 2 50, Phase 1/2 20, Phase 1 35) 2021: 211 trials (Observational 43, Not applicable 41, Phase 4 3, Phase 3 13, Phase 2/3 3, Phase 2 50, Phase 1/2 24, Phase 1 34) 2022: 162 trials (Observational 40, Not applicable 31, Phase 4 1, Phase 3 9, Phase 2/3 3, Phase 2 31, Phase 1/2 16, Phase 1 31) 2023: 177 trials (Observational 42, Not applicable 27, Phase 4 5, Phase 3 11, Phase 2/3 2, Phase 2 39, Phase 1/2 17, Phase 1 34) 2024: 200 trials (Observational 56, Not applicable 38, Phase 4 5, Phase 3 7, Phase 2/3 1, Phase 2 48, Phase 1/2 14, Phase 1 31) 2025: 199 trials (Observational 61, Not applicable 50, Phase 4 2, Phase 3 4, Phase 2/3 1, Phase 2 32, Phase 1/2 14, Phase 1 35)

Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.

Trials started per year
Year Trials started
2026 (partial year) 182
2025 199
2024 200
2023 177
2022 162
2021 211
2020 193
2019 179
2018 179
2017 169

Showing 10 of 37 earlier years.

Start your 14-day trial Email me all 37 earlier years as a PDF

Forecast of the full-year count, planned starts included, not rows of this table: about 210 trials starting in 2026 and about 200 in 2027, the average of the 24 months through September, counted as registered and carried forward. The rows of this table count trials registered so far with a start date in the year, planned starts included; the forecast looks ahead to the count for the whole year, so it is not the same measure. In backtests on conditions of this size, forecasts made part-way through the year were typically off by about 13 percent and ran about 12 percent low against the count later registered; forecasts made before the year began were off by about 19 percent and ran about 17 percent low against the count later registered, and had about the same error as repeating last year's count. These figures rest on a few years of history (target years from 2018 to 2025, varying by figure), place each condition as it is mapped today rather than as it was then, and score against a count for the newest year that was still being revised. Only condition series were scored.

Prediction, not a registry value: median of 36 months from start to primary completion across 475 trials still running at the 2026-10-09 snapshot; registered median of 38 months across 2,152 trials with a primary completion typed Actual. Source: ClinicalTrials.gov / AACT (CTTI), public domain.

What phase are Neoplasms, Connective and Soft Tissue trials in? (10)

Shown in this order: phase order.

Show the trials by phase as a table
Trials by phase
Phase Trials
Phase 1 657
Phase 1/2 300
Phase 2 1,063
Phase 2/3 37
Phase 3 275
Phase 4 97
Not applicable 590
Observational 726
Expanded access 36
Unknown 1

How many Neoplasms, Connective and Soft Tissue trials are recruiting? (13)

Shown in this order: the order a trial moves through, from not yet recruiting to unknown.

Trials by recruitment status
Status Trials
Not yet recruiting 133
Recruiting 605
Enrolling by invitation 17
Active, not recruiting 252
Available 13

Showing 5 of 13 statuses.

Start your 14-day trial Email me all 13 statuses as a PDF

Status as registered on ClinicalTrials.gov. Each trial is counted once.

Which lead sponsors run the most Neoplasms, Connective and Soft Tissue trials? (5)

Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.

Lead sponsors
Sponsor Trials
National Cancer Institute (NCI) 242
Children's Oncology Group 76
Novartis Pharmaceuticals 48
Gynecologic Oncology Group 33
European Organisation for Research and Treatment of Cancer - EORTC 32

Which drugs are being tested for Neoplasms, Connective and Soft Tissue? (5)

Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.

Drugs tested
Drug Trials
Cytoxan 116
Imatinib 80
(nab)-paclitaxel 58
Irinotecan 48
PEMBROLIZUMAB 47

Interventions as named in the registry (10)

Shown in this order: most trials first.

Interventions as named in the registry
Drug Trials
Doxorubicine 175
Ifosfamid 96
Radiation Therapy 77
Cisplatin 1 62
Vincristina 62

Showing 5 of 10 interventions.

Start your 14-day trial Email me all 10 interventions as a PDF

These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.

Which serious adverse events do Neoplasms, Connective and Soft Tissue trials report? (10)

Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.

Serious adverse events in this condition's trials
Adverse event Subjects affected Trials
Febrile neutropenia 732 123
Vomiting 634 193
Abdominal pain 552 165
Neutrophil count decreased 536 82
Anemia 484 100

Showing 5 of 10 adverse events.

Start your 14-day trial Email me all 10 adverse events as a PDF

Which publications cover Neoplasms, Connective and Soft Tissue? (3)

Shown in this order: major-topic papers first, then newest, then most linked to trials.

Publications
Publication Journal Year Major topic
Pazopanib for treatment of advanced extraskeletal myxoid chondrosarcoma: a multicentre, single-arm, phase 2 trial. The Lancet. Oncology 2019 Yes
Identification of microRNA biomarkers for response of advanced soft tissue sarcomas to eribulin: Translational results of the EORTC 62052 trial. European journal of cancer (Oxford, England : 1990) 2017 Yes
Results of sub-analysis of a phase 2 study on trabectedin treatment for extraskeletal myxoid chondrosarcoma and mesenchymal chondrosarcoma. BMC cancer 2016 Yes

Sub-conditions in MeSH (5)

MeSH descendants one level down with at least one trial, most trials first.

Not on this page

Not measured: delivery record.

Checked, with nothing recorded for this condition: prevalence and rare-disease identity.

Browse all condition evidence pages